Moreover, MYD88 and CD79B were identified as cancer driver genes in the high-risk group, which is in good agreement with the previous findings that MYD88 and CD79B mutations have been associated with tumor response and survival in DLBCL patients (31–33). Here, CD79B is linked to cancer.